AI-generated analysis. Always verify with the original filing.
Intensity Therapeutics, Inc. filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock, effective at 4:01 p.m. ET on February 18, 2026, with trading on a post-split basis beginning February 19, 2026 on Nasdaq under ticker INTS and new CUSIP 45828J 202. The split reduces outstanding shares from approximately 63,346,579 to 2,533,863 without changing authorized shares, to regain compliance with Nasdaq's minimum bid price requirement.
Event Type
Disclosure
Mandatory
Variant
8-K
Material Modifications to Rights of Security Holders. To the extent required by Item 3.03, the disclosure set forth in Item 5.03 is incorporated herein by refer
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 13, 2026, Intensity Therapeutics, Inc. (the “Company”) filed with the Secr
Other Information. On February 13, 2026, the Company issued a press release announcing the Reverse Stock Split. The press release is filed as Exhibit 99.1 and i
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation